Literature DB >> 12195386

Pneumolysin activates the synthesis and release of interleukin-8 by human neutrophils in vitro.

Riana Cockeran1, Chrisna Durandt, Charles Feldman, Timothy J Mitchell, Ronald Anderson.   

Abstract

The effects that the Streptococcus pneumoniae-derived, proinflammatory toxin, pneumolysin (8.37 and 41.75 ng/mL), has on the production of interleukin (IL)-8 and tumor-necrosis factor (TNF)-alpha by human neutrophils have been investigated in vitro. Total and extracellular IL-8 and TNF-alpha were assayed by enzyme-linked immunosorbent assay, and flow cytometry and colorimetric procedures were used to detect intracellular cytokine and cytokine messenger RNA, respectively. Treatment of neutrophils with pneumolysin either alone or in combination with the chemotactic tripeptide, N-formyl-l-methionyl-l-leucyl-l-phenylalanine (1 microM), resulted in a time-dependent (maximal at 6 h) increase in synthesis and release of IL-8 but not of TNF-alpha, which was associated with increased expression of IL-8 messenger RNA transcripts and was abrogated by either cycloheximide (10 microg/mL) or depletion of Ca(2+) from the cell-suspending medium. These interactions between the toxin and neutrophils may contribute to the exaggerated pulmonary inflammatory responses caused by pneumolysin-producing strains of the pneumococcus.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12195386     DOI: 10.1086/341563

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

Review 1.  Bacteraemic pneumococcal pneumonia: current therapeutic options.

Authors:  Charles Feldman; Ronald Anderson
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  CD4-T-lymphocyte interactions with pneumolysin and pneumococci suggest a crucial protective role in the host response to pneumococcal infection.

Authors:  Aras Kadioglu; William Coward; M Joseph Colston; Colin R A Hewitt; Peter W Andrew
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

Review 3.  Membrane assembly of the cholesterol-dependent cytolysin pore complex.

Authors:  Eileen M Hotze; Rodney K Tweten
Journal:  Biochim Biophys Acta       Date:  2011-07-31

4.  Neutrophil responses to CRP are not dependent on polymorphism of human FcgammaRIIA (R131H).

Authors:  J A Rodríguez; K B Bodman-Smith; J G Raynes
Journal:  Clin Exp Immunol       Date:  2004-11       Impact factor: 4.330

5.  Epithelial cells are sensitive detectors of bacterial pore-forming toxins.

Authors:  Adam J Ratner; Karen R Hippe; Jorge L Aguilar; Matthew H Bender; Aaron L Nelson; Jeffrey N Weiser
Journal:  J Biol Chem       Date:  2006-03-06       Impact factor: 5.157

Review 6.  Pharmacological approaches to regulate neutrophil activity.

Authors:  G R Tintinger; R Anderson; C Feldman
Journal:  Semin Immunopathol       Date:  2013-03-15       Impact factor: 9.623

7.  THP-1 monocytes up-regulate intercellular adhesion molecule 1 in response to pneumolysin from Streptococcus pneumoniae.

Authors:  Justin Thornton; Larry S McDaniel
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

8.  The apoptotic response to pneumolysin is Toll-like receptor 4 dependent and protects against pneumococcal disease.

Authors:  Amit Srivastava; Philipp Henneke; Alberto Visintin; Sarah C Morse; Victoria Martin; Claire Watkins; James C Paton; Michael R Wessels; Douglas T Golenbock; Richard Malley
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

9.  Streptococcus pneumoniae-induced caspase 6-dependent apoptosis in lung epithelium.

Authors:  Bernd Schmeck; Ralph Gross; Phillipe Dje N'Guessan; Andreas C Hocke; Sven Hammerschmidt; Tim J Mitchell; Simone Rosseau; Norbert Suttorp; Stefan Hippenstiel
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

10.  Role of Toll-like receptors 2 and 4 in pulmonary inflammation and injury induced by pneumolysin in mice.

Authors:  Mark C Dessing; Robert A Hirst; Alex F de Vos; Tom van der Poll
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.